Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial
早期三阴性乳腺癌新辅助治疗：纳武利尤单抗或纳武利尤单抗联合伊匹木单抗：一项 II 期适应性试验
期刊:Nature Medicine
影响因子:58.7
doi:10.1038/s41591-024-03249-3
Iris Nederlof # ,Olga I Isaeva # ,Manon de Graaf ,Robbert C A M Gielen ,Noor A M Bakker ,Adrianne L Rolfes ,Hannah Garner ,Bram Boeckx ,Joleen J H Traets ,Ingrid A M Mandjes ,Michiel de Maaker ,Thomas van Brussel ,Maksim Chelushkin ,Elisa Champanhet ,Marta Lopez-Yurda ,Koen van de Vijver ,José G van den Berg ,Ingrid Hofland ,Natasja Klioueva ,Ritse M Mann ,Claudette E Loo ,Frederieke H van Duijnhoven ,Victoria Skinner ,Sylvia Luykx ,Emile Kerver ,Ekaterina Kalashnikova ,Marloes G J van Dongen ,Gabe S Sonke ,Sabine C Linn ,Christian U Blank ,Karin E de Visser ,Roberto Salgado ,Lodewyk F A Wessels ,Caroline A Drukker ,Ton N Schumacher ,Hugo M Horlings ,Diether Lambrechts ,Marleen Kok
